81292 -hyphen 81294 MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-hyphenpolyposis colorectal cancer, Lynch syndrome) gene analysis 81295 -hyphen 81297 MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-hyphenpolyposis colorectal cancer, ...
Colon cancer surgery: pathological quality control is essential for optimal outcomes. Colorectal Dis. 2018;20(suppl 1):34-35. doi:10.1111/codi.14075 PubMedGoogle ScholarCrossref 13. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. ...
the C-statistic of combined model was 0.76 (95% CI: 0.69, 0.83) for females and 0.77 (95% CI: 0.70, 0.84) for males. When considering CRC risk separately for colon and rectum, the C-statistic of the combined model reached 0.79 (95% CI: 0.74, 0.85) for colon cancer and 0.82...
thus providing a grade C recommendation for prostate cancer screening for men in that age group. The USPSTF systematically reviewed evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators...
The association between human papillomavirus (HPV) and anal cancer and the similarities between the “transitional zones” within the cervix and anus have raised questions regarding the medical biology of anal cancer. In recent years, increased rates of
1227 Accesses 10 Citations Metrics details Abstract The goal of this study was to explore diagnostic colonoscopy completion in adults with abnormal screening fecal immunochemical test (FIT) results. This was a secondary analysis of the Strategies and Opportunities to Stop Colon Cancer in Priority ...
For every cancer reported, medical record abstraction included the cancer diagnosis date and the International Classification of Disease for Oncology, second version (ICD-O-2) code. Vital status was obtained by the administration of the Annual Study Update questionnaire, reports from relatives, friends...
Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. J. Am. Board Fam. Med. 2016, 29, 672–681. [Google Scholar] [CrossRef] [PubMed] [Green Version] Niedermaier, T.; Weigl, K.; Gies, A.; Hoffmeister, M.; Brenner, H. Accuracy ...
Hydrophilic statin use for 180–545 days was associated with 53% lower overall mortality (OR = 0.47; 95% CI = 0.29–0.77). In subgroup analyses, beneficial effects on both cancer development and mortality persisted in patients ≥65 years old, patients with normal blood pressure, and patients ...
context. Several reasons (Figure 2) were selected when given in fixed statements but did not appear in the open answers, e.g., ‘My GP (general practitioner) did not talk with me about it (FIT screening)’ (applicable for 11.2%), or ‘I don’t want to know if I have cancer’ (...